. 2011 Jul 28;68(1):39–53. doi: 10.1007/s00228-011-1095-3

Table 3.

Development of population PK model for garenoxacin

Model no.	Model construction ^a	CV ω²_CL/F	CV ω²_Vd/F	OBJ (p value)
End of phase II stage (interim analysis)^b
1	Base model	19.4%	18.3%	356.754
2	CL/F = θ₁ + θ₂ × (CL_CR − 85)	20.6%	21.0%	271.509 (p < 0.001)
End of phase III stage (final analysis)^c
1	Base model	37.4%	37.0%	1475.267
2	CL/F = θ₁ + θ₂ × (CL_CR − 85)	19.5%	32.4%	1403.379 (p < 0.001)
2	V/F = θ₃	19.5%	32.4%	1403.379 (p < 0.001)
3	CL/F = θ₁ + θ₂ × (CL_CR − 85)	20.6%	16.4%	1309.516 (p < 0.001)
3	V/F = θ₃ × (WT/55) ^θ4	20.6%	16.4%	1309.516 (p < 0.001)
4	CL/F = θ₁ + θ₂ × (CL_CR − 85)	20.6%	16.4%	1298.040 (p < 0.001)
4	V/F = θ₃ × (WT/55) ^θ4 + θ₅ × GEN	20.6%	16.4%	1298.040 (p < 0.001)
5 (final model)	CL/F = θ₁ + θ₂ × (CL_CR − 85) + θ₃ × (WT − 55)	20.1%	15.8%	1292.110 (p = 0.015)
5 (final model)	V/F = θ₄ × (WT/55) ^θ5 + θ₆ × GEN	20.1%	15.8%	1292.110 (p = 0.015)

CV, Coefficient of variance; OBJ, objective function value

^aCL/F, Total body clearance; V/F, distribution volume/F; GEN, gender (1: male; 0: female); θ, population mean parameters

^bFirst-order method (NONMEM version V, level 1.0)

^cFirst-order conditional estimation method with interaction (NONMEM version VI, level 2.0)